公开(公告)号：US20240350439A1

公开(公告)日：2024-10-24

申请号：US18759093

申请日：2024-06-28

申请人： METIMEDI PHARMACEUTICALS CO., LTD.

发明人： Chong Hwan CHANG ,  Keun-Yeong JEONG

IPC分类号： A61K31/19 ,  A23L33/10 ,  A23L33/165 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K33/06 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40 ,  A61K47/44 ,  A61P35/00

CPC分类号： A61K31/19 ,  A23L33/10 ,  A23L33/165 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/5026 ,  A61K9/5042 ,  A61K33/06 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40 ,  A61K47/44 ,  A61P35/00 ,  A23V2002/00 ,  A23V2200/308 ,  A23V2250/042 ,  A23V2250/1578

摘要： The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

公开(公告)号：US12121050B2

公开(公告)日：2024-10-22

申请号：US17976724

申请日：2022-10-28

申请人： LAMINARIA GROUP AB

发明人： Olov Sköld ,  Anna Ström ,  Martin Ahnoff

IPC分类号： A23L33/125 ,  A23L2/38 ,  A23L2/52 ,  A23L29/231 ,  A23L29/256 ,  A23L29/30 ,  A23L33/10 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A23L33/175

CPC分类号： A23L33/125 ,  A23L2/38 ,  A23L2/52 ,  A23L29/231 ,  A23L29/256 ,  A23L29/30 ,  A23L33/10 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A23L33/175 ,  A23V2002/00 ,  A23V2200/33 ,  A23V2250/06 ,  A23V2250/16 ,  A23V2250/161 ,  A23V2250/1614 ,  A23V2250/1642 ,  A23V2250/21 ,  A23V2250/5026 ,  A23V2250/50722 ,  A23V2250/5114 ,  A23V2250/5118 ,  A23V2250/606 ,  A23V2250/61 ,  A23V2250/62 ,  A23V2250/628 ,  A23V2250/708 ,  A23V2002/00 ,  A23V2200/32 ,  A23V2200/33 ,  A23V2250/032 ,  A23V2250/06 ,  A23V2250/1578 ,  A23V2250/16 ,  A23V2250/161 ,  A23V2250/1614 ,  A23V2250/1638 ,  A23V2250/1642 ,  A23V2250/21 ,  A23V2250/50 ,  A23V2250/5026 ,  A23V2250/5072 ,  A23V2250/60 ,  A23V2250/708

摘要： The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

公开(公告)号：US20240335517A1

公开(公告)日：2024-10-10

申请号：US18493262

申请日：2023-10-24

申请人： VITAMERICA UG (HAFTUNGSBESCHRANKT)

发明人： Daniel Henry WYROBNIK ,  Isaac Harry WYROBNIK

IPC分类号： A61K38/52 ,  A23L29/00 ,  A23L33/10 ,  A23L33/18 ,  A23L33/20 ,  A61K9/48 ,  A61K38/44 ,  A61K38/54 ,  A61P1/00

CPC分类号： A61K38/52 ,  A23L29/06 ,  A23L33/10 ,  A23L33/18 ,  A23L33/20 ,  A61K9/485 ,  A61K9/4858 ,  A61K38/44 ,  A61K38/54 ,  A61P1/00 ,  C12Y101/99011 ,  C12Y302/0102 ,  C12Y302/01026 ,  C12Y503/01005 ,  A23V2002/00 ,  A61K2300/00

摘要： There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.

公开(公告)号：US20240325410A1

公开(公告)日：2024-10-03

申请号：US18386447

申请日：2023-11-02

申请人： The Brain Health Project, LLC

发明人： Morris Notelovitz

IPC分类号： A61K31/593 ,  A23L33/10 ,  A61K31/353 ,  A61K31/4748 ,  A61K31/566 ,  A61K31/592 ,  G01N33/68

CPC分类号： A61K31/593 ,  A23L33/10 ,  A61K31/353 ,  A61K31/4748 ,  A61K31/566 ,  A61K31/592 ,  G01N33/6896 ,  A23V2002/00 ,  A61K2300/00 ,  G01N2800/28 ,  G01N2800/52

摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

公开(公告)号：US20240325363A1

公开(公告)日：2024-10-03

申请号：US18281480

申请日：2022-03-03

申请人： ONCOCROSS CO.,LTD. ,  UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

发明人： Yi Rang KIM ,  Sang Yun PARK ,  Jin Woo CHOI ,  Soo Min LEE

IPC分类号： A61K31/4439 ,  A23L33/10 ,  A61P35/00

CPC分类号： A61K31/4439 ,  A23L33/10 ,  A61P35/00

摘要： The present invention relates to an anticancer agent capable of overcoming EGFR-TKI resistance in KRAS mutant cancer. GW8510 according to the present invention is an effective inhibitor against oncogenic mutation, especially, KRAS mutation, which is associated to resistance of the anticancer agent EGFR inhibitor and remarkably inhibits expression of both the wild-type and various mutants of KRAS, whereby the drug itself exhibits an anticancer effect, surmounts anticancer agent resistance, and noticeably promotes the death of anticancer agent-resistant cancer cells when used in combination with an anticancer agent. Thus, the inhibitor finds advantages applications in treating cancers, especially anticancer agent resistant cancers.

公开(公告)号：US20240316097A1

公开(公告)日：2024-09-26

申请号：US18677521

申请日：2024-05-29

申请人： Vector Vitale IP LLC

发明人： Max Temnik ,  Sergey Gurin ,  Oleksandr Balakin ,  Peter Novak

IPC分类号： A61K33/30 ,  A23L33/10 ,  A23L33/16 ,  A61K31/704 ,  A61K33/00 ,  A61K33/06 ,  A61K45/06

CPC分类号： A61K33/30 ,  A23L33/10 ,  A23L33/16 ,  A61K31/704 ,  A61K33/00 ,  A61K33/06 ,  A61K45/06

摘要： A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.

公开(公告)号：US12083218B2

公开(公告)日：2024-09-10

申请号：US17447453

申请日：2021-09-13

申请人： Johnson & Johnson Consumer Inc.

发明人： Gregory E. Koll ,  Gerard P. McNally ,  Vipul Dave

IPC分类号： A61K9/00 ,  A23L27/00 ,  A23L27/30 ,  A23L33/10 ,  A61K9/127 ,  A61K31/426

CPC分类号： A61K9/0056 ,  A23L27/33 ,  A23L27/84 ,  A23L33/10 ,  A61K9/127 ,  A61K31/426

摘要： The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

公开(公告)号：US12083151B2

公开(公告)日：2024-09-10

申请号：US17938184

申请日：2022-10-05

申请人： Seres Therapeutics, Inc.

发明人： Matthew R. Henn ,  Geoffrey von Maltzahn ,  Anthony Mario D'Onofrio ,  Kevin Daniel Litcofsky ,  David Arthur Berry ,  David N. Cook ,  Noubar B. Afeyan ,  John Grant Aunins

IPC分类号： A61K39/02 ,  A23L33/10 ,  A23L33/135 ,  A23P10/30 ,  A61K9/00 ,  A61K9/48 ,  A61K35/74 ,  A61K35/742 ,  A61K38/13 ,  A61K39/08 ,  A61K45/06

CPC分类号： A61K35/742 ,  A23L33/127 ,  A23L33/135 ,  A23P10/30 ,  A61K9/0053 ,  A61K9/4891 ,  A61K35/74 ,  A61K38/13 ,  A61K45/06 ,  A23V2002/00 ,  Y02A50/30

摘要： Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

公开(公告)号：US12083084B2

公开(公告)日：2024-09-10

申请号：US17384218

申请日：2021-07-23

申请人： REPLICON HEALTH OY

发明人： Petteri Hirvonen ,  Peter Eriksson ,  Risto Kaksonen

IPC分类号： A61K31/191 ,  A23L2/52 ,  A23L33/10 ,  A61K31/19 ,  A61P21/06

CPC分类号： A61K31/191 ,  A23L2/52 ,  A23L33/10 ,  A61K31/19 ,  A61P21/06 ,  A23V2002/00 ,  A23V2200/316

摘要： The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.

公开(公告)号：US12043594B2

公开(公告)日：2024-07-23

申请号：US17059762

申请日：2019-05-30

申请人： EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION

发明人： Kong Joo Lee ,  Hee-Yoon Lee ,  Je Jin Lee ,  Hongsoo Lee ,  Ji-wan Seo ,  Hwang Suk Kim ,  Bo-kyung Kim ,  Ji Soo Shin

IPC分类号： C07C43/23 ,  A23L33/00 ,  A23L33/10 ,  A61K9/00 ,  A61K31/09 ,  A61K31/12 ,  A61K31/337 ,  A61P35/00 ,  C07C49/175

CPC分类号： C07C43/23 ,  A23L33/10 ,  A23L33/40 ,  A61K9/0056 ,  A61K31/09 ,  A61K31/12 ,  A61K31/337 ,  A61P35/00 ,  C07C49/175 ,  A23V2002/00

摘要： The present disclosure provides a novel biphenyl derivative compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to the present disclosure may induce cancer cell death by damaging mitochondria and inducing ATP depletion in cells which are in a nutrient-starved state such as a glucose-starved state, which is the normal environment of cancer cells. In addition, it is an Nm23-H1/NDPK activity-increasing substance that may suppress cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.